Results 21 to 30 of about 4,644,977 (251)

Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review

Frontiers in Oncology, 2021
Most pituitary tumors are considered benign adenomas, and only 0.1%–0.2% of them present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary adenomas (PAs) lie between benign adenomas and true malignant PCs and are defined as ...
Congxin Dai, Siyu Liang, Bowen Sun, Yong Li, Jun Kang   +4 more
doaj   +1 more source

Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease

Scientific Reports, 2021
We evaluated changes in the complement system resulting from anti-vascular endothelial growth factor (VEGF) in eyes with age-related choroidal neovascularization (CNV) including neovascular age-related macular degeneration, pachychoroid neovasculopathy ...
Keiichiro Tanaka, Yasuharu Oguchi, Tomoko Omori, Yumi Ishida, Hiroaki Shintake, Ryutaro Tomita, Akihito Kasai, Masashi Ogasawara, Yukinori Sugano, Kanako Itagaki, Akira Ojima, Takeshi Machida, Hideharu Sekine, Tetsuju Sekiryu   +13 more
doaj   +1 more source

Current perspectives on the use of anti-VEGF drugs as adjuvant therapy in glaucoma [PDF]

, 2016
The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening ...
Morales-Fernández, L., Polo Llorens, V., Perucho González, Lucía, Herrero Vanrell, María Del Rocío, García-Feijoo, Julián, Pablo Júlvez, Luis, Martínez-de-la-Casa, José María, Polo Llorens, Vicente, García-Feijoo, J., Andrés-Guerrero, V., Perucho-González, L., Konstas, A.G P., Martínez De La Casa Fernández-Borrella, José María, Morales-Fernández, Laura, Júlvez, Luis Pablo, Andrés Guerrero, Vanesa, García Feijoo, Julián, Saenz-Francés, Federico, Pablo Júlvez, L., Perucho-González, Lucía, Konstas, Anastasios Georgios P., Herrero-Vanrell, R., Martínez-de-la-Casa, J.M., Andrés-Guerrero, Vanessa, Morales Fernández, Laura, Sáenz Francés, Federico, Llorens, Vicente Polo, Konstas, Anastasios-Georgios, Herrero-Vanrell, Rocío, Saenz-Francés, F.   +29 more
core   +1 more source

Clinical Course and Results of Anti-VEGF Therapy of Retinopathy of Prematurity

Oftalʹmologiâ, 2021
The clinical course of active retinopathy after anti-VEGF therapy, the possibility and timing of recurrence of the disease, anatomical and functional outcomes of treatment are widely discussed in the press, not fully studied and relevant.Purpose: to ...
L. A. Katargina, E. N. Demchenko, L. V. Kogoleva   +2 more
doaj   +1 more source

Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options

Cells, 2021
Anti-vascular endothelial growth factor (anti-VEGF) therapy currently plays a central role in the treatment of numerous retinal diseases, most notably exudative age-related macular degeneration (eAMD), diabetic retinopathy and retinal vein occlusions ...
Josh O. Wallsh, Ron P. Gallemore
doaj   +1 more source

Anti-VEGF Therapy in Myopic CNV [PDF]

, 2021
In this narrative-review, we report the most recent data from the literature of anti-vascular endothelial growth factor treatment for myopic choroidal neovascularization (mCNV). Myopic CNV is the most frequent sight-threatening complication of pathologic
Lisa Toto, Olivia Costantino, Luca Di Antonio, Rodolfo Mastropasqua   +3 more
core   +1 more source

Clinical preferences and trends of anti‐vascular endothelial growth factor treatments for diabetic macular edema in Japan

Journal of Diabetes Investigation, 2019
Aims/Introduction To determine the current clinical preferences of anti‐vascular endothelial growth factor (VEGF) treatment protocols for diabetic macular edema (DME) in Japan. Materials and Methods This was a descriptive cross‐sectional study.
Masahiko Sugimoto, Hideyuki Tsukitome, Fumiki Okamoto, Tetsuro Oshika, Tetsuo Ueda, Masanori Niki, Yoshinori Mitamura, Hiroto Ishikawa, Fumi Gomi, Shigehiko Kitano, Hidetaka Noma, Masahiko Shimura, Shozo Sonoda, Osamu Sawada, Masahito Ohji, Kozo Harimoto, Masaru Takeuchi, Yoshihiro Takamura, Mineo Kondo, Taiji Sakamoto   +19 more
doaj   +1 more source

Efficacy and effectiveness of anti-VEGF or steroids monotherapy versus combination treatment for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis

BMC Ophthalmology, 2022
Background Retinal vein occlusion (RVO) is the main cause of retinal vascular blindness. Laser photocoagulation therapy is the regarded as the standard treatment for branch retinal vein occlusion (BRVO) in the guidelines, but it is not effective for ...
Wuyue Zhang, Yuan Liu, Aimin Sang
doaj   +1 more source

Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies [PDF]

, 2005
Vascular endothelial growth factors ( VEGF)- A, - C and - D are members of the proangiogenic VEGF family of glycoproteins. VEGF-A is known to be the most important angiogenic factor under physiological and pathological conditions, while VEGF-C and VEGF-D
Jauch, Karl-Walter, Kleespies, A., Bruns, Christiane J.   +2 more
core   +1 more source

The Role of Laser Photocoagulation in Treating Diabetic Macular Edema in the Era of Intravitreal Drug Administration: A Descriptive Review

Medicina, 2023
Background and Objectives: This study aimed to elucidate the role of laser photocoagulation therapy in the treatment of diabetic macular edema (DME) as an alternative to, or in conjunction with, the first-line treatment, anti-vascular endothelial growth ...
Miho Nozaki, Ryota Ando, Toshiya Kimura, Fusae Kato, Tsutomu Yasukawa   +4 more
doaj   +1 more source